IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Advanced Solid Tumours
- Small Cell Lung Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This study will be conducted in two parts. Part I of the study will be dose escalation evaluation to determine the MTD and/or RP2D of IMP4297 in combination with temozolomide. Part II of the study will be conducted in two RP2D expansion cohorts (sensitive ES-SCLC cohort and resistant ES-SCLC cohort)...
This study will be conducted in two parts. Part I of the study will be dose escalation evaluation to determine the MTD and/or RP2D of IMP4297 in combination with temozolomide. Part II of the study will be conducted in two RP2D expansion cohorts (sensitive ES-SCLC cohort and resistant ES-SCLC cohort) to further evaluate the anti-tumor activity, safety and tolerability of this regimen in ES-SCLC patients.
Tracking Information
- NCT #
- NCT04434482
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon